Che‐Leung Law

6.5k total citations · 1 hit paper
99 papers, 5.0k citations indexed

About

Che‐Leung Law is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Immunology. According to data from OpenAlex, Che‐Leung Law has authored 99 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Radiology, Nuclear Medicine and Imaging, 44 papers in Oncology and 44 papers in Immunology. Recurrent topics in Che‐Leung Law's work include Monoclonal and Polyclonal Antibodies Research (58 papers), HER2/EGFR in Cancer Research (21 papers) and T-cell and B-cell Immunology (20 papers). Che‐Leung Law is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (58 papers), HER2/EGFR in Cancer Research (21 papers) and T-cell and B-cell Immunology (20 papers). Che‐Leung Law collaborates with scholars based in United States, United Kingdom and Netherlands. Che‐Leung Law's co-authors include Edward A. Clark, Sidorenko Sp, Kristine A. Gordon, Iqbal S. Grewal, Peter D. Senter, Alan F. Wahl, Charles G. Cerveny, Kerry Klussman, Svetlana O. Doronina and Damon L. Meyer and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Che‐Leung Law

98 papers receiving 4.9k citations

Hit Papers

1 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity

2003 668 citations Charles G. Cerveny, Damon L. Meyer et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Che‐Leung Law United States	36	2.3k	1.7k	1.6k	1.5k	668	99	5.0k
Rudolf Schmits Germany	25	2.7k 1.2×	1.1k 0.7×	1.4k 0.9×	515 0.3×	798 1.2×	52	4.5k
Kerry Klussman United States	19	1.8k 0.8×	1.4k 0.8×	792 0.5×	938 0.6×	431 0.6×	37	3.4k
Pina M. Cardarelli United States	25	1.1k 0.5×	1.1k 0.6×	1.0k 0.6×	756 0.5×	261 0.4×	66	2.9k
Bahija Jallal United States	47	2.0k 0.9×	1.3k 0.8×	2.6k 1.6×	707 0.5×	465 0.7×	86	5.5k
Kenya Shitara Japan	42	2.8k 1.2×	1.3k 0.8×	5.6k 3.5×	4.3k 2.8×	303 0.5×	86	7.7k
Bryan Irving United States	20	5.5k 2.4×	4.1k 2.4×	1.7k 1.1×	917 0.6×	322 0.5×	44	7.8k
Meike Burger Germany	29	1.8k 0.8×	1.7k 1.0×	1.1k 0.7×	182 0.1×	650 1.0×	46	3.6k
John P. McKearn United States	23	1.4k 0.6×	939 0.5×	1.9k 1.2×	427 0.3×	416 0.6×	56	3.7k
Joaquı́n Teixidó Spain	39	1.3k 0.6×	1.6k 0.9×	2.0k 1.3×	347 0.2×	158 0.2×	71	4.4k
Marcel Spaargaren Netherlands	43	1.2k 0.5×	1.4k 0.8×	3.1k 1.9×	224 0.1×	1.3k 1.9×	98	5.8k

Countries citing papers authored by Che‐Leung Law

Since Specialization

Citations

This map shows the geographic impact of Che‐Leung Law's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Che‐Leung Law with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Che‐Leung Law more than expected).

Fields of papers citing papers by Che‐Leung Law

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Che‐Leung Law. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Che‐Leung Law. The network helps show where Che‐Leung Law may publish in the future.

Co-authorship network of co-authors of Che‐Leung Law

This figure shows the co-authorship network connecting the top 25 collaborators of Che‐Leung Law. A scholar is included among the top collaborators of Che‐Leung Law based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Che‐Leung Law. Che‐Leung Law is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Austin, Richard J., Bryan D. Lemon, Wade H. Aaron, et al.. (2020). Preclinical Characterization of HPN536, a Trispecific, T-Cell–Activating Protein Construct for the Treatment of Mesothelin-Expressing Solid Tumors. Clinical Cancer Research. 27(5). 1452–1462. 35 indexed citations

Lemon, Bryan D., Wade H. Aaron, Richard J. Austin, et al.. (2018). Abstract 1773: HPN424, a half-life extended, PSMA/CD3-specific TriTAC for the treatment of metastatic prostate cancer. Cancer Research. 78(13_Supplement). 1773–1773. 6 indexed citations

Li, Fu, Michelle Ulrich, Mechthild Jonas, et al.. (2017). Tumor-Associated Macrophages Can Contribute to Antitumor Activity through FcγR-Mediated Processing of Antibody–Drug Conjugates. Molecular Cancer Therapeutics. 16(7). 1347–1354. 53 indexed citations

Fu, Li, Kim K. Emmerton, Mechthild Jonas, et al.. (2016). Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models. Cancer Research. 76(9). 2710–2719. 231 indexed citations

Greene, Lloyd A., et al.. (2014). Lack of anti‐factor Xa assay standardization results in significant low molecular weight heparin (enoxaparin) dose variation in neonates and children. Journal of Thrombosis and Haemostasis. 12(9). 1554–1557. 16 indexed citations

Lewis, Timothy S., Kim K. Emmerton, Jeffrey Lau, et al.. (2011). Distinct Apoptotic Signaling Characteristics of the Anti-CD40 Monoclonal Antibody Dacetuzumab and Rituximab Produce Enhanced Antitumor Activity in Non-Hodgkin Lymphoma. Clinical Cancer Research. 17(14). 4672–4681. 27 indexed citations

Sutherland, May Kung, Changpu Yu, Martha E. Anderson, et al.. (2010). 5-Azacytidine enhances the anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia. mAbs. 2(4). 440–448. 24 indexed citations

Oflazoglu, Ezogelin, Tamar E. Boursalian, Weiping Zeng, et al.. (2009). Blocking of CD27-CD70 Pathway by Anti-CD70 Antibody Ameliorates Joint Disease in Murine Collagen-Induced Arthritis. The Journal of Immunology. 183(6). 3770–3777. 47 indexed citations

Sutherland, May Kung, Changpu Yu, Timothy S. Lewis, et al.. (2009). Anti-leukemic activity of Lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia. mAbs. 1(5). 481–490. 32 indexed citations

10.

McEarchern, Julie A., Leia M. Smith, Charlotte F. McDonagh, et al.. (2008). Preclinical Characterization of SGN-70, a Humanized Antibody Directed against CD70. Clinical Cancer Research. 14(23). 7763–7772. 70 indexed citations

11.

Lewis, Timothy S., Jamie B. Miyamoto, May Kung Sutherland, et al.. (2007). The humanized anti-CD40 monoclonal antibody, SGN-40, signals apoptosis in non-Hodgkin's lymphoma by dual mechanisms. Molecular Cancer Therapeutics. 6. 1 indexed citations

12.

Gerber, Hans‐Peter, Ivan J. Stone, Mechthild Jonas, et al.. (2007). Humanized anti-CD19 auristatin antibody-drug conjugates display potent antitumor activity in preclinical models of B-cell malignancies. Molecular Cancer Therapeutics. 6. 2 indexed citations

13.

Hatjiharissi, Evdoxia, Allen W. Ho, Lian Xu, et al.. (2006). Preclinical In Vitro and In Vivo Evidence Support a Therapeutic Role for the CD70 Directed Monoclonal Antibody (SGN-70) in Waldenstrom’s Macroglobulinemia (WM).. Blood. 108(11). 2490–2490. 2 indexed citations

14.

Law, Che‐Leung, Julie A. McEarchern, Charles G. Cerveny, et al.. (2005). The Humanized Anti-CD40 Monoclonal Antibody SGN-40 Targets Hodgkin’s Disease Cells through Multiple Mechanisms.. Blood. 106(11). 1476–1476. 5 indexed citations

15.

McEarchern, Julie A., Charlotte F. McDonagh, Allen W. Ho, et al.. (2005). A Humanized Anti-CD70 Monoclonal Antibody Targets CD70-Expressing Multiple Myeloma.. Blood. 106(11). 1591–1591. 4 indexed citations

16.

Law, Che‐Leung, et al.. (2002). Expression and characterization of recombinant soluble human CD3 molecules: presentation of antigenic epitopes defined on the native TCR–CD3 complex. International Immunology. 14(4). 389–400. 11 indexed citations

17.

Gibbins, Jonathan M., Judith Asselin, Richard W. Farndale, et al.. (1996). Tyrosine Phosphorylation of the Fc Receptor γ-Chain in Collagen-stimulated Platelets. Journal of Biological Chemistry. 271(30). 18095–18099. 193 indexed citations

18.

Yanaga, Fumi, Alastair W. Poole, Judith Asselin, et al.. (1995). Syk interacts with tyrosine-phosphorylated proteins in human platelets activated by collagen and cross-linking of the Fc γ-IIA receptor. Biochemical Journal. 311(2). 471–478. 127 indexed citations

19.

Law, Che‐Leung, Sidorenko Sp, Kay Draves, et al.. (1994). Molecular cloning of human Syk. A B cell protein-tyrosine kinase associated with the surface immunoglobulin M-B cell receptor complex.. Journal of Biological Chemistry. 269(16). 12310–12319. 126 indexed citations

20.

Villablanca, Judith G., Janet Anderson, Melinda L. Moseley, et al.. (1990). Differentiation of normal human pre-B cells in vitro.. The Journal of Experimental Medicine. 172(1). 325–334. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact